So you think there's a solid chance the need for leukapheresis at CRL Memphis could be for DCVax? I think it's common for blood cancers and CAR-T. If we are pretty sure those are not being done then what else could there be but DCVax?
Bio, initially Cognate had one customer that being in NWBO. Suspect Cognate was working/looking to diversify their customer portfolio when CRL acquired them. Obviously, CRL has a broad customer portfolio making Cognate a good fit. Not to mention the inherent strategic value of the Memphis FedEx hub location for a biologic production facility.
It’s my opinion Cognate had not obtained additional sustaining customers before being acquired by CRL. And it is also likely Cognate performed some “one off” project type work for other customers during this time
News 
Market Data 
Discover 
AI
